Drug intelligence / Profile preview

ITZ-DerMap

Development stage: Preclinical
Lead developer: ArrayPatch
Modality: Small Molecules
Administration: Topical

Overview

ITZ-DerMap is a proprietary microneedle patch delivery system for the antifungal drug itraconazole, developed by ArrayPatch, a spin-out from University College Cork. It is specifically designed for the treatment of onychomycosis (fungal nail infection). The patch utilizes microneedle technology to penetrate the nail plate and deliver the active pharmaceutical ingredient directly to the site of infection in the nail bed. This localized delivery approach aims to improve efficacy while avoiding the systemic side effects and drug-drug interactions typically associated with oral itraconazole therapy, such as hepatotoxicity.

Brand names: ITZ-DerMap
Other names: Itraconazole microneedle patch

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on ITZ-DerMap.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITZ-DerMap.

Explore the full profile